Aswin Ratna Kansakar

Aswin Ratna Kansakar

Auto-generated profile, based on publicly available information

Aswin Ratna Kansakar

Department of Internal Medicine, AMITA Health Saint Francis Hospital, Evanston, IL

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2017 in PeerJ
Verified
Journal Article
Open access
PDF file
AEAbdelrahman Elshafay
Abdelrahman Elshafay
NTNgo Xuan Tinh
Ngo Xuan Tinh
SSSamar Salman
Samar Salman
YSYara Saber Shaheen
Yara Saber Shaheen
EOEman Bashir Othman
Eman Bashir Othman
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
Ginsenoside Rk1 (G-Rk1) is a unique component created by processing the ginseng plant (mainly Sung Ginseng (SG)) at high temperatures. The aim of our study was to systematically review the pharmacological effects of G-Rk1. We utilized and manually searched eight databases to selectin vivoandin vitrooriginal studies that provided information about biological, pharmaceutical effects of G-Rk1 and were published up to July 2017 with no restriction on language or study design. Out of the 156 papers identified, we retrieved 28 eligible papers in the first skimming phase of research. Several articles largely described the G-Rk1 anti-cancer activity investigating “cell viability”, “cell proliferation inhibition”, “apoptotic activity”, and “effects of G-Rk1 on G1 phase and autophagy in tumor cells” either alone or in combination with G-Rg5. Others proved that it has antiplatelet aggregation activities, anti-inflammatory effects, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis. In conclusion, G-Rk1 has a significant anti-tumor effect on liver cancer, melanoma, lung cancer, cervical cancer, colon cancer, pancreatic cancer, gastric cancer, and breast adenocarcinoma againstin vitrocell lines.In vivoexperiments are further warranted to confirm these effects.

1 March 2021 in Obesity Medicine
Verified
Journal Article
Open access
ESEkta Shrestha
Ekta Shrestha
MCMariam Charkviani
Mariam Charkviani
CMClio Musurakis
Clio Musurakis
AKAswin Ratna Kansakar
Aswin Ratna Kansakar
ADAmrit Devkota
Amrit Devkota
GNGuillermo Rodriguez Nava
Guillermo Rodriguez Nava
Type 2 diabetes (T2D) is the leading non-communicable disease worldwide and is associated with several microvascular and macrovascular complications. Individuals with T2D are more prone to acquiring selected types of infections and are more susceptible to complications due to these infections. This study aimed to evaluate the relationship between T2D and COVID-19 in the community setting. This was a single-center retrospective analysis that included 147 adult patients with laboratory-confirmed COVID-19 admitted to a community hospital. Demographics, medical history, symptoms and signs, laboratory findings, complications during the hospital course, and treatments were collected and analyzed. The Kaplan-Meier method was used to describe the probability of intubation in patients with T2D as compared with patients without T2D. The hazard ratio for intubation in the survival analysis was estimated using a bivariable Cox proportional-hazards model. Of 147 patients, 73 (49.7%) had a history of T2D. Patients with T2D had higher requirement of ICU admission (31.5% vs 12.2%; p=.004), higher incidence of ARDS (35.6% vs 16.2%, p=.007), higher rates of intubation (32.9% vs 12.2%, p=0.003), and higher use neuromuscular blocking agents (23.3% vs 9.5%, p=.02). In the survival analysis at 28 days of follow-up, patients with T2D showed an increased hazard for intubation (HR 3.00; 95% CI, 1.39 to 6.46). In our patient population, patients with COVID-19 and T2D showed significantly higher ARDS incidence and intubation rates. The survival analysis also showed that after 28 days of follow-up, patients with T2D presented an increased risk for shorter time to intubation.

1 November 2017 in Medicine
Verified
Journal Article
Open access
PDF file
MMMostafa Ebraheem Morra
Mostafa Ebraheem Morra
AEAbdelrahman Elshafay
Abdelrahman Elshafay
AKAswin Ratna Kansakar
Aswin Ratna Kansakar
GMGhaleb Muhammad Mehyar
Ghaleb Muhammad Mehyar
NDNguyen Phan Hoang Dang
Nguyen Phan Hoang Dang
KHKenji Hirayama
Kenji Hirayama
Persistent vomiting is mentioned as a symptom of a large variety of systemic disorders. It is commonly used interchangeably with chronic, recurrent, or intractable vomiting and widely used as a warning sign of severe illness in dengue infection. However, it has been poorly defined in the medical literature. Therefore, we aimed to systematically review a definition of persistent vomiting in the medical literature. A systematic search was done through; PubMed, Google Scholar, Web of Science, Scopus, VHL, WHO-GHL, Grey Literature Report, POPLINE, and SIGLE for the last 10 years. Consensus on the definition was considered to be reached if at least 50% of studies described the same definition using the Delphi consensus technique. Of 2362 abstracts reviewed, 15 studies were selected based on the inclusion criteria. Three studies used the same definition. Another 2 studies defined it as vomiting of all foods and fluid in 24 hours. Three studies defined persistent vomiting in the units of days or weeks. Four studies used the number of episodes: ≥2 episodes 15 minutes apart, >3 episodes in 12 hours, and >3 episodes within 24 hours. No consensus for the definition was found among authors. This is a point of concern that needs to be addressed by further studies.

1 January 2018 in Journal of Cardiology Case Reports
Verified
Journal Article
Open access
SDShahriar Dadkhah
Shahriar Dadkhah
ESEkta Shrestha
Ekta Shrestha
AKAswin Ratna Kansakar
Aswin Ratna Kansakar
NFNegar Faramarzi
Negar Faramarzi
APAmishi Parekh
Amishi Parekh
PTPhilippos Tsourkas
Philippos Tsourkas